Abstract
It is well known that inter-individual variability exists in the responses to many drugs. Many nongenetic factors, such as age, sex, diet, and organ function, are known to affect the therapeutic effects of drugs. However, recent advances in pharmacogenomics have revealed that genetic polymorphisms also significantly influence both the efficacy and the toxicity of drugs. Mutations in the genes encoding drug-metabolizing enzymes, transporters, and target molecules may alter their expression, activity, or affinity to drugs, thereby influencing the drugs’ pharmacokinetics and pharmacodynamics. Numerous studies have reported on the correlations between therapeutic outcomes and polymorphisms in drug-metabolizing enzymes, transporters, target molecules, and DNA repair enzymes. These pharmacogenomic discoveries are expected to be useful for the individualization and optimization of cancer chemotherapy.
Access this article
We’re sorry, something doesn't seem to be working properly.
Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.
Similar content being viewed by others
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Yamayoshi, Y., Iida, E. & Tanigawara, Y. Cancer pharmacogenomics: international trends. Int J Clin Oncol 10, 5–13 (2005). https://doi.org/10.1007/s10147-004-0467-4
Received:
Issue Date:
DOI: https://doi.org/10.1007/s10147-004-0467-4